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Abstract
Background: In pulmonary arterial hypertension (PAH), the six-minute walk test (6MWT) is believed to be representative of
patient’s daily life physical activities (DLPA). Whether DLPA are decreased in PAH and whether the 6MWT is representative of
patient’s DLPA remain unknown.
Methods: 15 patients with idiopathic PAH (IPAH) and 10 patients with PAH associated with limited systemic sclerosis (PAH-
SSc) were matched with 15 healthy control subjects and 10 patients with limited systemic sclerosis without PAH. Each
subject completed a 6MWT. The mean number of daily steps and the mean energy expenditure and duration of physical
activities .3 METs were assessed with a physical activity monitor for seven consecutive days and used as markers of DLPA.
Results: The mean number of daily steps and the mean daily energy expenditure and duration of physical activities .3
METs were all reduced in PAH patients compared to their controls (all p,0.05). The mean number of daily steps correlated
with the 6MWT distance for both IPAH and PAH-SSc patients (r=0.76, p,0.01 and r=0.85, p,0.01), respectively.
Conclusion: DLPA are decreased in PAH and correlate with the 6MWT distance. Functional exercise capacity may thus be a
useful surrogate of DLPA in PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is characterized by a
progressive increase in pulmonary vascular resistance ultimately
leading to right heart failure and death. Despite considerable
improvements in long-term prognosis with the modern advances
in PAH-specific therapies [1], most patients display persistent and
significant dyspnea, exercise intolerance and poor health-related
quality of life. Because of its discriminative properties in idiopathic
PAH [2–6], exercise capacity has been used as the primary
endpoint in most of the recent placebo-controlled randomized
trials in PAH [1]. Exercise capacity is also considered as a
benchmark for disease severity, prognosis and response to therapy
in PAH, and its routine assessment is currently recommended at
baseline and follow-up [3–7].
In PAH, exercise tolerance is most commonly assessed by the
six-minute walk test (6MWT), with the assumption that the
distance walked during this test is representative of patient’s daily
life activities [8]. However, the relationship between the distance
walked during the 6MWT and the level of daily life physical
activities (DLPA) has not been documented in PAH. Moreover,
decreased level of DLPA has been subjectively reported by PAH
patients [9]. However, whether PAH patients are objectively less
physically active to a level that may theoretically contribute to
deconditioning remains unknown.
The aims of this study were to test the hypothesis that the level
of DLPA of PAH patients is markedly lower compared to sedentary
healthy subjects, and that the 6MWT could be a useful surrogate
of DLPA among PAH patients.
Methods
Ethics statement
The institutional ethics committee (Comite ´ d’e ´thique de la
recherche de l’Institut de cardiologie et de pneumologie de
Que ´bec, protocol number: CE ´R 20142) approved the research
protocol and all subjects gave written consent prior to study
enrolment.
Subjects
Consecutive patients with idiopathic pulmonary arterial hyper-
tension (IPAH, n=15) and with pulmonary arterial hypertension
associated with limited systemic sclerosis (PAH-SSc, n=10) were
recruited at the Institut Universitaire de cardiologie et de
pneumologie de Que ´bec. The definition of limited systemic
sclerosis was based on Leroy criteria [10]. The PAH diagnosis
was made according to recent guidelines [11]. All patients
displayed significant PAH, defined as a mean pulmonary artery
pressure .25 mmHg at rest with a pulmonary capillary wedge
pressure ,15 mmHg [12]. Recent right heart catheterization
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patients with no change in their PAH therapy, in stable clinical
condition over the last 4 months and belonging to functional
classes II or III defined by the New York Heart Association
(NYHA) functional classification were eligible. Exclusion criteria
were as follow: (1) unstable PAH defined as recent syncope or
NYHA functional class IV; (2) left ventricular ejection fraction
,40% of predicted; (3) significant restrictive (more than minimal
lung fibrosis on CT scan or total lung capacity ,70% of predicted)
or obstructive (FEV1/FVC ,70%) lung disease. IPAH patients
were individually matched for age, gender and body mass index
(BMI) with healthy control subjects (CTRL, n=15) recruited by
advertisement in the community. Similarly, PAH-SSc patients
were matched with patients with limited systemic sclerosis (SSc,
n=10) after excluding PAH (normal physical examination and
pulmonary function tests, and systolic pulmonary arterial pressure
by Doppler-echocardiography of 30 (6) mmHg). Neither PAH
patients, SSc patients or healthy controls were enrolled in a
structured physical activity program before or during the study. All
the subjects were told to maintain their usual activities during the
study. As the time of the year may greatly influence weekly energy
expenditure, particularly in Northern climate countries, PAH
patients and matched controls were concomitantly recruited.
Study design
After reviewing the medical history and obtaining anthropo-
metric measurements, a 6MWT was performed according to
recent recommendations [8]. Individual results were compared to
predicted values [13].
Subjects were then equipped with a physical activity monitor
(SenseWearH Pro armband; BodyMedia Inc., Pittsburgh, PA,
USA). This device, measuring 8.865.662.1 cm and weighing
82 g, was positioned on patients’ right upper arm (triceps brachii)
skin at midpoint between the acromion and the olecranon. The
monitor contains a biaxial accelerometer (longitudinal and
transverse) and multiple sensors (galvanic skin response, heat
flux, skin temperature and near-body ambient temperature).
While activity questionnaires often yielded to inaccurate
physical activities assessments [14–15], this multiaxial device
provides objective, accurate, individualized and detailed de-
scription of activity patterns such as time and intensity of
physical activities and has been validated in diverse populations
including patients with chronic diseases [14,16–19]. The data
provided by the sensors are stored minute by minute and the
energy expenditure determination is based on specific algo-
rithms. This device provides the energy expenditure (kilocalo-
ries) and the time spent (minutes) of physical activities above a
pre-determined intensity level (e.g. metabolic equivalents
[METs]) as well as the number of steps.
Each subject was instructed to wear the physical activity
monitor for the entire day (except sleep time and while showering
or bathing) for seven consecutive days. To ensure that the
measured DLPA characteristics were representative of patient’s
usual functional status, patients were asked to avoid unfamiliar
activities and fill a physical activity journal log. DLPA were
defined a priori by: 1) the mean number of daily steps, 2) the
mean daily energy expended during physical activities inducing a
metabolic demand .3 METs [20], and 3) the mean daily
duration spent in physical activities inducing a metabolic demand
.3 METs. The American College of Sports Medicine suggests
the definition of the metabolic demand representative of
moderate activity to be age-dependent in healthy subjects in
order to take into account the impact of normal aging on daily
exercise level [21]. However, this definition may not be suitable
for chronically diseased subjects. For this reason, a metabolic
demand .3M E T sw a sd e f i n e dapriori as a marker of moderate
activity in our patients, as previously done in similarly impaired
patients with chronic respiratory diseases [18,22]. DLPA were
analyzed using the SenseWearH Pro software version 6.1.0.1523
(BodyMedia Inc., Pittsburgh, PA, USA).
Statistical analysis
Quantitative variables were expressed as mean (SD) and
qualitative variables as proportion. Chi-square test or Fischer’s
exact were used to compare qualitative variables and one-way
ANOVA was used to compare mean values for quantitative
variables. Posteriori comparisons among the four groups were
performed using the Tukey’s technique. The normality and
variance assumptions were verified with the Shapiro-Wilk and
with Brown and Forsythe’s variation of Levene’s tests respec-
tively. Pearson correlation coefficients corrected for multiple
testing (Bonferroni) were used to evaluate relationships between
the distance walked during the 6MWT and the three markers of
DLPA as well as the right atrial pressure and the cardiac index.
The results were considered significant with p-values #0.05 and
#0.01 when corrected for multiple testing. DLPA characteristics
were normalized for the time the physical activity monitor was
worn. The data were analyzed using the statistical package
program SAS 9.2 (Service Pack 4, SAS Institute Inc., Cary,
NC).
Table 1. Characteristics of the study population.
CTRL IPAH SSc PAH-SSc
n=15 n=15 n=10 n=10
Demographics
Age (yr) 46 (16) 47 (15) 58 (9) 58 (10)
Sex (F/M) (10/5) (10/5) (9/1) (9/1)
BMI (kg/m
2) 26 (5) 27 (8) 25 (5) 26 (5)
Pulmonary hemodynamic
RAP (mm Hg) NA 7 (2) NA 5 (3)
mPAP (mm Hg) NA 46 (13) NA 41 (13)
PCWP (mm Hg) 10 (3) 9 (3)
CI (L/minNm
22) NA 2.9 (0.8) NA 3.1 (0.8)
PVRi (WUNm
2) NA 13.8 (6.4) NA 10.5 (5.9)
NYHA Functional
class
(II/III) NA (11/4) NA (5/5)
Exercise tolerance (6MWT)
Distance (m) 670 (64) 401 (89)* 502 (55) 349 (129){
Distance (% pred) 120 (20) 75 (14) * 100 (10) 72 (21) {
Values are mean (SD).
*p,0.05 IPAH vs. CTRL.
{p,0.05 PAH-SSc vs. SSc.
Table legend: yr, years; F, female; M, male; BMI, body mass index; kg, kilogram;
RAP, right atrial pressure; mPAP, mean pulmonary artery pressure; PCWP,
pulmonary capillary wedge pressure; CI, cardiac index; PVRi, pulmonary vascular
resistance index; WU, Wood units; NYHA, New York Heart Association; 6MWT,
six-minute walk test; m, meters; % pred, percentage of predicted value; CTRL,
healthy control subjects; IPAH, patients with idiopathic pulmonary arterial
hypertension; SSc, subjects with limited systemic sclerosis without PAH; PAH-
SSc, patients with pulmonary arterial hypertension associated with limited
systemic sclerosis.
doi:10.1371/journal.pone.0027993.t001
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Subjects’ characteristics
The characteristics of the study population are shown in
Table 1. PAH patients were well matched with their respective
controls for age, gender and BMI. They were treated with
bosentan (n=13), epoprostenol (n=6), sildenafil (n=2), sitaxsen-
tan (n=2), ambrisentan (n=1) and calcium channel blockers
(n=1). Finally, 16 and 9 PAH patients were classified as NYHA
functional class II and III, respectively.
DLPA characteristics and functional status
The four groups demonstrated an equally good compliance with
the physical activity monitor, wearing it for 12.9 (1.0), 12.5 (1.2),
11.9 (1.2), and 12.0 (2.0) hours/day for CTRL, IPAH, SSc and
PAH-SSc respectively. As depicted in Figure 1A, IPAH and PAH-
SSc patients presented significantly lower mean number of daily
steps when compared with their respective controls (5041 (3357)
vs. 9189 (3093) steps/day, p,0.01 for IPAH and CTRL
respectively, and 3234 (2437) vs. 5810 (2226) steps/day, p=0.01
for PAH-SSc and SSc respectively). PAH patients also showed
significant decreases in their participation in physical activities
inducing a metabolic demand .3 METs (energy expenditure and
duration). (Figure 1B, 1C).
The mean number of daily steps correlated with the distance
walked during the 6MWT for IPAH and PAH-SSc patients
(r=0.76, p,0.01 and r=0.85, p,0.01), respectively (Figure 2).
Also, the energy expenditure and the duration of physical activities
inducing a metabolic demand .3 METs correlated with the
distance walked during the 6MWT amongst PAH patients
(r=0.52 and r=0.52 for energy expenditure and duration
respectively, both p,0.01). DLPA were also progressively de-
creased with the worsening of NYHA functional class (Figure 3).
Neither right atrial pressure nor cardiac index correlated with the
6MWT or with DLPA in PAH (all p.0.30).
Discussion
Compared to healthy controls and SSc patients, IPAH and
PAH-SSc patients presented lower mean number of daily steps
and lower participation to moderately intense physical activities
(.3 METs). Amongst IPAH and PAH-SSc patients, DLPA
characteristics correlated with functional exercise capacity ex-
pressed by the distance walked during the 6MWT, suggesting that
this test may be a surrogate of PAH patients’ DLPA. The mean
number of daily steps and functional exercise capacity decreased
progressively as the NYHA functional class worsened. To our
knowledge, this is the first study characterizing DLPA and its
relation with objective exercise capacity and NYHA functional
class in PAH.
Exercise tolerance is generally assessed by the 6MWT in PAH.
The distance walked during this simple and low cost test was found
to correlate with patients’ maximal oxygen consumption, NYHA
functional class and survival [3]. The 6MWT is also thought to be
representative of DLPA in PAH, an assumption that has never
been verified. This study confirmed that the 6MWT correlates
with DLPA in PAH. Among DLPA characteristics, the mean daily
steps strongly correlated with the distance walked during the
6MWT. Similarly, DLPA decreased as NYHA functional class
worsened. As the ultimate goal of PAH therapies is to improve
patients’ functional capacity in their daily life rather than the
Figure 1. Daily life physical activities in pulmonary arterial hypertension patients and control groups. Mean number of daily steps
(panel A), mean daily energy expended during physical activities inducing a metabolic demand .3 METs (panel B), and mean daily duration of
physical activities inducing a metabolic demand .3 METs. (panel C) in healthy control subjects (CTRL; dark bars), patients with idiopathic pulmonary
arterial hypertension (IPAH; grey bars), patients with limited systemic sclerosis without PAH (SSc; hatched bars), and patients with pulmonary arterial
hypertension associated with limited systemic sclerosis (PAH-SSc; open bars). Values are mean 6 SD. * p,0.01 vs. CTRL; 1 p#0.01 vs. SSc; # p=0.02
vs SSc. Figure legend: kcal, kilocalories; n, number.
doi:10.1371/journal.pone.0027993.g001
Figure 2. Correlation between exercise capacity and daily steps
in pulmonary arterial hypertension patients. Correlation between
the six-minute walk test (6MWT) distance and the mean daily steps in
patients with idiopathic pulmonary arterial hypertension (IPAH; panel A)
and in patients with pulmonary arterial hypertension associated with
limited systemic sclerosis (PAH-SSc; panel B). Figure legend: n, number;
min, minute.
doi:10.1371/journal.pone.0027993.g002
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improvements observed during this test with PAH therapies could
be clinically relevant for PAH patients. As the level of DLPA is a
parameter of increasing clinical interest and constitutes an
important patient-centered outcome, whether changes in 6MWT
observed in response to treatment translate into changes in DLPA
remains to be confirmed.
Despite recent improvements in long-term prognosis of PAH
patients [1], a majority of patients displays persistent dyspnea and
significant exercise intolerance. Exercise intolerance has been
traditionally attributed to limited cardiac reserve, altered chrono-
tropic response, ventilatory inefficiency and to ventilation/
perfusion mismatch [23–24]. More recently, muscle dysfunction
was pointed out as potentially contributing to exercise intolerance
in PAH patients [25–27]. Although mechanisms leading to muscle
dysfunction remain to be elucidated, inactivity may also contribute
to exercise intolerance and muscle weakness in PAH. The present
study documented lower DLPA in PAH compared to matched
controls even if the majority (64%) of the patients were in NYHA
functional class II. According to the step-defined hierarchy
documented by Tudor-Locke et al. [28], daily steps below 5000
and between 5000 and 7500 are representative of «sedentary lifestyle
index» and «low active», respectively. Thus, most PAH patients have
adopted a sedentary lifestyle to a level comparable to older patients
with severe chronic obstructive pulmonary disease (GOLD III)
[18].
Because physical activity has been consistently associated with
enhanced health related quality of life, interest to improve DLPA is
Figure 3. Relation between daily life physical activities and exercise capacity with the New York Heart Association functional class.
Mean number of daily steps (panel A), mean daily energy expended during physical activities inducing a metabolic demand .3 METs (panel B), mean
daily duration of physical activities inducing a metabolic demand .3 METs (panel C), and six-minute walk test (6MWT) distance (panel D) in healthy
control subjects (CTRL; open bars) and in patients with pulmonary arterial hypertension in New York Heart Association (NYHA) functional class II (dark
bars) and III (grey bars). Values are mean (SD). * p,0.05 and { p,.001 vs. CTRL; { p,0.001 vs NYHA II. Figure legend: n, number; kcal, kilocalories; min,
minute; m; meter.
doi:10.1371/journal.pone.0027993.g003
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studies suggested that pulmonary rehabilitation in PAH may result
in increased exercise capacity, and quality of life [29–31], and
recent guidelines suggested that PAH patients may benefit from
low graded aerobic exercise [32]. DLPA may thus influence
exercise capacity of PAH patients and explain the correlation
between the 6MWT and the DLPA. It is noteworthy, however, that
the effect of pulmonary rehabilitation on patients’ DLPA as well as
the determination of which specific interventions and patients’
characteristics are associated with more benefits and less risks
remain unknown in PAH. Moreover, DLPA may also be
influenced by several non-physiological factors including emotion-
al and psychological state, depression, anxiety, social support,
body image and self-efficacy [33-34]. Those were not assessed in
our study. Not surprisingly, DLPA were not related to the distance
walked during the 6MWT in controls, suggesting that DLPA are
more related to external factors than exercise limitation in
controls. It also reinforces the concept that the 6MWT suffers
from a ceiling effect that cannot discriminate the subjects with
higher exercise and occupational capacities [8].
In conclusion, the participation in daily physical activities was
reduced in PAH to a level that may contribute to further decrease
exercise capacity. Moreover, the NYHA functional class and the
6MWT distance, which are routinely used as a markers of disease
severity, prognosis and response to therapy in PAH, are also
representative of patients’ daily physical activity participation.
Whether improvements in exercise capacity observed with PAH-
specific therapies also increase the level of DLPA, an important
patient-centered outcome, remain to be documented.
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